Immunex Corporation

Type: Company
Name: Immunex Corporation
Nationality: United States
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

RLO Announces Class Action Lawsuit By Enbrel Patient Against Immunex and Caremark CVS Over Mail Order Caremark Prescriptions

A California man filed a class action lawsuit against Immunex and Caremark CVS alleging that the pharmacy fails to properly refrigerate best-selling drug Enbrel when filling a mail order Caremark prescription. As a result, thousands of seniors and disabled ... [Published PRWeb - Oct 17 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure

Reality bites: Amgen’s (NASDAQ: AMGN) decision to leave Washington state is a serious blow to our local bioscience ecosystem. Those who think that all of those people who got laid off (or choose not to relocate) will be able to find biopharma jobs here ... [Published Xconomy - Oct 07 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

What Are The Best-Selling Drugs Of 2014?

What are the top-selling pharmaceutical drugs of the year?While 2014 is not yet over, it's possible to explore to answer to this question after making a few educated assumptions.According to research from IMS Health, a healthcare services, information ... [Published Benzinga.com - Oct 03 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Ovarian Cancer Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment

Research and Markets (http://www.researchandmarkets.com/research/3v55j8/ovarian_cancer) has announced the addition of the "Ovarian Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Ovarian ... [Published Individual.com - Oct 02 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

Biotech Pioneer to Keynote Governor's Life Sciences Summit & Annual Meeting October 24

SEATTLE--(BUSINESS WIRE)-- Chris Rivera, President of the Washington Biotechnology & Biomedical Association (WBBA) announced today that Steven Gillis, PhD, Managing Director, ARCH Venture Partners , and a longtime veteran of the biotechnology industry ... [Published CNBC - Sep 25 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Orexigen Therapeutics (OREX) Presents at Bank of America Merrill Lynch Global Healthcare Conference (Transcript)

Steve Byrne - Bank of America Merrill LynchWell welcome to the last session of the day. My name is Steve Byrne. I am a Biotech Analyst for BofA Merrill in New York. And it’s a pleasure for me to host Orexigen. Mark Booth, Chief Commercial Officer is up ... [Published Seeking Alpha - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Survey: RA Drug Market Driven by Uptake of Oral Jak Inhibitors and Non–TNF-Alpha Biologics

Biosimilars expected to challenge branded biologicsDecision Resources Group, a health care research firm located in Burlington, Mass., finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion ... [Published PT Community - Sep 17 2014]
Entities: Biologics, Biology, Drugs
First reported May 14 2014 - Updated May 14 2014 - 1 reports

Stem cell research advocate to speak at Pregnancy Care Clinic banquet

Theresa Deisher will speak at the Pregnancy Care Clinic dessert banquet.— image credit: Contributed photoThe Pregnancy Care Clinic will have a dessert banquet this weekend and host an expert credited with discovering adult cardiac-derived stem cells.Theresa ... [Published South Whidbey Record - May 14 2014]
First reported Apr 27 2014 - Updated Apr 27 2014 - 1 reports

Ultragreen building is ready for challenge | Sunday Buzz

Denis Hayes, guiding spirit of the supergreen Bullitt Center office building on Capitol Hill, is pleased to report that in its first year the six-story structure has yielded some unanticipated benefits: Since using what he calls the “irresistible stairway” ... [Published Seattle Times - Apr 27 2014]

Quotes

Research and Markets (http://www.researchandmarkets.com/research/3v55j8/ovarian_cancer) has announced the addition of the "Ovarian Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering...

More Content

All (12) | News (12) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
RLO Announces Class Action Lawsuit By Enbrel Pa... [Published PRWeb - Oct 17 2014]
What Seattle Needs (Part 2): Dealing With Amgen... [Published Xconomy - Oct 07 2014]
What Are The Best-Selling Drugs Of 2014? [Published Benzinga.com - Oct 03 2014]
Ovarian Cancer Market Analysis 2014-2015 - API ... [Published Individual.com - Oct 02 2014]
Biotech Pioneer to Keynote Governor's Life Scie... [Published CNBC - Sep 25 2014]
Orexigen Therapeutics (OREX) Presents at Bank o... [Published Seeking Alpha - Sep 18 2014]
Survey: RA Drug Market Driven by Uptake of Oral... [Published PT Community - Sep 17 2014]
Stem cell research advocate to speak at Pregnan... [Published South Whidbey Record - May 14 2014]
Ultragreen building is ready for challenge | Su... [Published Seattle Times - Apr 27 2014]
Cloned transmembrane receptor for 24-hydroxylat... [Published PharmCast - Mar 16 2014]
Catalent Announces Two Senior Appointments to E... [Published PRWeb - Feb 26 2014]
Amgen planning to buy Onyx for about $10.4 billion [Published Topnews.in - Aug 26 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.